BSE filing, NSE: ALIVUS. Summary written from the filing by ALFA Finder's alert engine.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,393.90
- Market cap
- ₹17,113 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.4×Sector 46.1×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Legal & Regulatory
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
- Value
- ₹0.51 Cr
Alivus Life Sciences Acquisition Worth ₹14.04 Cr
Alivus Life Sciences acquired a 9.21% stake in Torrent Urja 19 Private Limited for Rs. 14.04 Crore. The investment supports its renewable energy and carbon neutrality goals.
- Value
- ₹14.04 Cr
Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Other debt & borrowing announcements
All →Aavas Financiers Debt & Borrowing: ₹22.3 Cr
Aavas Financiers certified timely half-yearly interest payment of ₹22.30 Crore on its NCDs (ISIN INE216P07241). No redemption payment was made during the period.
- Value
- ₹22.30 Cr
Black Buck Debt & Borrowing: ₹40 Cr
BlackBuck's board approved a ₹40 Crore corporate guarantee to Axis Bank securing a term loan for subsidiary Blackbuck Finserve. No immediate financial impact on the company.
- Value
- ₹40.00 Cr
Neogen Chemicals Debt & Borrowing: ₹1.69 Cr
Neogen Chemicals paid monthly interest of ₹1.69 Crore on its ₹200 Cr NCDs (ISIN INE136S07013) on 28 Oct 2026, fulfilling its Reg 57(1) obligation.
- Value
- ₹1.69 Cr
Dar Credit & Capital Debt & Borrowing: ₹0.13 Cr
Dar Credit & Capital confirmed payment of monthly interest of Rs.13.38 Lakh on ISIN INE04Q907199. The Reg 57(1) certificate records the debt-servicing obligation met on 29 Oct 2026.
- Value
- ₹0.13 Cr
Nilkamal Debt & Borrowing
Nilkamal filed its statutory auditor's security cover certificate for secured NCDs as of September 30, 2026. The auditor confirmed the company maintained the required 125% cover.
HDB Financial Services Debt & Borrowing: ₹11.52 Cr
HDB Financial Services paid Rs.11.52 Crore yearly interest on its perpetual debt instruments on the due date, 29 October 2026. The payment was made on time with no delay reported.
- Value
- ₹11.52 Cr